Symbiosis Pharmaceutical Services
Stirling, UK
Program data pending ClinicalTrials.gov matching
· Last scored 2026-04-02
76.8
Signal Score
✓ FDA Inspections (1)
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
✓ MHRA GMP (9)
Quick Facts: Symbiosis Pharmaceutical Services
- Signal Score
- 76.8/100 (as of 2026-04-02)
- Quality Compliance
- 100.0/100
- Headquarters
- Stirling, UK
- Modalities
- Cell Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA Inspections1 on record
Warning Letters0
Last InspectionNo Action Indicated (NAI) (2025-01-31)
MHRA GMP Certificates9 on record
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Stirling, UK
Source: SEC EDGAR, press monitoring, company profiles
1 manufacturing site
1 manufacturing site: Stirling, UK
Modalities: Cell Therapy
Capacity assessment: 53.0/100
FDA Inspection History
2025-01
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-01-31 | Stirling | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Apr 05, 2026
MHRA GMP Compliance 9 certificates
2025-02
2025-02
2025-02
2025-02
2024-08
2024-08
2023-09
2023-09
2017-06
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK MIA(IMP) 40211 Insp IMP 40211/405290-0019[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/405290-0020[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2025-02-04 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/37423042-0005[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4TS | 2025-02-04 | COMPLIANT |
| UK MIA(IMP) 40211 Insp IMP 40211/33209260-0005[I] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK MIA 40211 Insp GMP 40211/33209260-0006[H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2024-08-20 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [H] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK GMP 40211 Insp GMP/IMP 40211/33209260-0001 [V] | SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED | STIRLING FK9 4NF | 2023-09-08 | COMPLIANT |
| UK MIA 42671 Insp GMP 42671/13896012-0003[H] | COX PHARMACEUTICAL LIMITED | STIRLING FK7 7RP | 2017-06-01 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.2
CAR-T, Cell Therapy, iPSC, Gene Editing
Ori Biotech
London, UK
Signal Score: 78.1
CAR-T, Cell Therapy
eXmoor Pharma
Bristol, UK
Signal Score: 78.1
Cell Therapy, AAV
HiTech Health
London, UK
Signal Score: 76.8
Cell Therapy